Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation

C. Madsen; M. B. Pedersen; M. Ø. Vase; K. Bendix; M. B. Møller; P. Johansen; B. A. Jensen; P. Jensen; L. Munksgaard; P. D. Brown; E. K. Segel; Francesco A. D'Amore

doi:10.1093/annonc/mdu537

Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation

C. Madsen, M. B. Pedersen, M. Ø. Vase, K. Bendix, M. B. Møller, P. Johansen, B. A. Jensen, P. Jensen, L. Munksgaard, P. D. Brown, E. K. Segel, Francesco A. D'Amore^*

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

46 Citationer (Scopus)

Abstract

The purpose of this work was to determine whether the outcome of patients with transformed indolent lymphoma improved if they, after R-chemo, also received upfront autologous stem-cell transplantation. Upfront autologous stem-cell transplant improved the outcome in sequential, but not composite/discordant TIL. The beneficial impact of ASCT was greater in patients, who were rituximab-nai¨ve at transformation.

Originalsprog	Engelsk
Tidsskrift	Annals of Oncology
Vol/bind	26
Udgave nummer	2
Sider (fra-til)	393-399
Antal sider	7
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdu537
Status	Udgivet - 2015
Udgivet eksternt	Ja

Bibliografisk note

Publisher Copyright:
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Adgang til dokumentet

10.1093/annonc/mdu537

Citationsformater

Madsen, C., Pedersen, M. B., Vase, M. Ø., Bendix, K., Møller, M. B., Johansen, P., Jensen, B. A., Jensen, P., Munksgaard, L., Brown, P. D., Segel, E. K., & D'Amore, F. A. (2015). Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. Annals of Oncology, 26(2), 393-399. https://doi.org/10.1093/annonc/mdu537

@article{eee6747107974d98812af0668754e813,

title = "Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation",

abstract = "The purpose of this work was to determine whether the outcome of patients with transformed indolent lymphoma improved if they, after R-chemo, also received upfront autologous stem-cell transplantation. Upfront autologous stem-cell transplant improved the outcome in sequential, but not composite/discordant TIL. The beneficial impact of ASCT was greater in patients, who were rituximab-nai¨ve at transformation.",

keywords = "Autologous stem-cell transplantation, Rituximab era, Transformed indolent lymphoma",

author = "C. Madsen and Pedersen, {M. B.} and Vase, {M. {\O}.} and K. Bendix and M{\o}ller, {M. B.} and P. Johansen and Jensen, {B. A.} and P. Jensen and L. Munksgaard and Brown, {P. D.} and Segel, {E. K.} and D'Amore, {Francesco A.}",

year = "2015",

doi = "10.1093/annonc/mdu537",

language = "English",

volume = "26",

pages = "393--399",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation

AU - Madsen, C.

AU - Pedersen, M. B.

AU - Vase, M. Ø.

AU - Bendix, K.

AU - Møller, M. B.

AU - Johansen, P.

AU - Jensen, B. A.

AU - Jensen, P.

AU - Munksgaard, L.

AU - Brown, P. D.

AU - Segel, E. K.

AU - D'Amore, Francesco A.

PY - 2015

Y1 - 2015

N2 - The purpose of this work was to determine whether the outcome of patients with transformed indolent lymphoma improved if they, after R-chemo, also received upfront autologous stem-cell transplantation. Upfront autologous stem-cell transplant improved the outcome in sequential, but not composite/discordant TIL. The beneficial impact of ASCT was greater in patients, who were rituximab-nai¨ve at transformation.

AB - The purpose of this work was to determine whether the outcome of patients with transformed indolent lymphoma improved if they, after R-chemo, also received upfront autologous stem-cell transplantation. Upfront autologous stem-cell transplant improved the outcome in sequential, but not composite/discordant TIL. The beneficial impact of ASCT was greater in patients, who were rituximab-nai¨ve at transformation.

KW - Autologous stem-cell transplantation

KW - Rituximab era

KW - Transformed indolent lymphoma

U2 - 10.1093/annonc/mdu537

DO - 10.1093/annonc/mdu537

M3 - Journal article

C2 - 25411416

AN - SCOPUS:84925341373

SN - 0923-7534

VL - 26

SP - 393

EP - 399

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -